Utilizing gene expression profiling for the identification of small cell lung cancer subtypes

Abstract

Abstract. Small cell lung cancer is a highly aggressive form of lung cancer associated with poor prognosis and limited treatment options. Gene expression profiling has emerged as a valuable tool for classifying SCLC into distinct molecular subtypes, each with its own unique therapeutic vulnerabilities and biomarkers. Recent studies have identified four primary subtypes: SCLC-A, SCLC-N, SCLC-P, and SCLC-Y, with additional classification into neuroendocrine (NE) high, NE-low, and non-NE tumors. Advanced understanding of the molecular characteristics of these subtypes presents new opportunities for targeted therapeutic approaches. The paper underscores the potential for a shift toward personalized therapy for SCLC, taking into account the inter- and intratumoral heterogeneity and dynamic subtype interconversion in response to treatment. Incorporating subtype-specific biomarkers in clinical trial designs could lead to the first-ever molecular biomarker-driven approach in the management of SCLC, greatly enhancing treatment effectiveness and patient outcomes.